Each of them [melatonin and supplement D] contribute to control disease activity, but in relation to seasonal changes specifically, melatonin plays a more powerful role than vitamin D in MS. Since seasonal flare-ups are also normal with other inflammatory conditions such as for example lupus and rheumatoid arthritis, Quintana and other MS experts believe the new research may one day have broader impact on treatment for these autoimmune complications. Dr. R. Glenn Smith, a neurologist at Houston Methodist Medical center in Texas, known as the new study surprising and potentially exciting, but there’s a lot of analysis that’s gone forward previously that’s led to this.That’s another group that could benefit from the new drugs, Martin said. ‘Familial hypercholesterolemia isn’t uncommon,’ he noted. ‘It affects about one in 300 to 500 people.’ Of the trials covered in the Annals review, half involved people who have familial hypercholesterolemia. Some of the various other trials focused on people who’d quit statins due to the side effects. However, that doesn’t mean the new drugs are totally safe. Martin said the main concern which has arisen in trials of the brand new drugs is the prospect of ‘neurocognitive effects.’ For example, some study individuals reported problems such as confusion and trouble attending to.